Cadila Healthcare is currently trading at Rs. 392.40, up by 3.95 points or 1.02% from its previous closing of Rs. 388.45 on the BSE.
The scrip opened at Rs. 397.40 and has touched a high and low of Rs. 400.70 and Rs. 389.15 respectively. So far 80298 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 400.70 on 3-Aug-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 400.70 and Rs. 350.35 respectively. The current market cap of the company is Rs. 39767.28 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.78% respectively.
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Carbidopa and Levodopa Extended-Release Capsules (US RLD - Rytary) in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.
This medication is used to treat the symptoms of Parkinson’s disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 295 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1497.10 |
Dr. Reddys Lab | 5990.00 |
Cipla | 1363.90 |
Zydus Lifesciences | 958.50 |
Lupin | 1587.40 |
View more.. |